ArticleCureus2024
Surgeon Perspectives on Descemetorhexis Without Endothelial Keratoplasty for Fuchs Endothelial Corneal Dystrophy: A UK National Survey.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo provide an insight into the current perspective of UK ophthalmic surgeons on the role of Descemetorhexis without endothelial keratoplasty (DWEK) for the management of Fuchs endothelial corneal dystrophy (FECD). MATERIALS AND
methodsA Google Form (Google, UK) was electronically distributed to UK ophthalmologists with a special interest in cornea from November 2023 to June 2024. The survey consisted of 13 mandatory questions.
resultsResponses were received from 36 ophthalmic surgeons from across the UK, with clinical experience ranging from 0.5 to 30 years. Descemet membrane endothelial keratoplasty (DMEK) and Descemet stripping (automated) endothelial keratoplasty (DSEK/DSAEK) were the most common approaches for managing FECD. Only four respondents had practiced DWEK, but 97.2% expressed interest in learning this technique (35/36). Additionally, 69.4% felt that DWEK would be beneficial only with RHO kinase inhibitors (25/36). All respondents agreed that the clinical field would benefit from randomised trials comparing DWEK to DMEK/DSAEK, and 97.2% were open to changing their clinical practice based on the findings of such trials (35/36). DISCUSSION: This article provides the first snapshot of UK ophthalmic surgeons' views on DWEK in FECD. DWEK has potential as a surgical technique in selective cases, particularly with RHO kinase inhibitors. Optimal visual outcomes with DWEK depend on careful patient selection, necessitating an evidence-based approach to define patient selection criteria. Future studies should compare visual and complication outcomes between DWEK and DMEK/DSAEK in clinical trials, incorporating RHO kinase inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.